This Biotech Has Lost 50%-Plus On Just One Drug; Why It's Still Trucking On

Evommune stock dropped Wednesday after its experimental eczema treatment flopped in midstage testing. The bearish news followed another miss for the drug in treating hives. The post This Biotech Has Lost 50%-Plus On Just One Drug; Why It's Still Trucking On appeared first on Investor's Business Daily.

Read it at Investor's Business Daily ↗

← Front page